A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07203001
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Still´s Disease

Eligibility Criteria

Sex
ALL
Age
1 Year - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • MAS825 — DRUG
    Experimental drug

Study Details

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease

Key Dates

Start date
Nov 3, 2025
Status verified
Apr 2026
Primary completion
May 24, 2029
Completion
May 24, 2029

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MAS825
    Experimental drug

Primary Outcome Measure

Number of participants with clinical response based on one set of response criteria [ Time Frame: Day 85 ]

Central Contacts

  • Novartis Pharmaceuticals
    1-888-669-6682
    [email protected]
  • Novartis Pharmaceuticals
    +41613241111

Locations (2)

FacilityCityStateZIPSite coordinators
Cincinnati Childrens HospitalCincinnatiOhio45229
Megan Quinlan-Waters
[email protected]
513-636-7261
Alexei Grom (PRINCIPAL_INVESTIGATOR)
Legacy Emanuel Research Hosp PortlandPortlandOregon97232
Brenna Bogle
[email protected]
+1 503 413 5447
Daniel Joseph Kingsbury (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cincinnati, OH

By research site
Cincinnati Childrens Hospital· Cincinnati, OHLegacy Emanuel Research Hosp Portland· Portland, OR